Cargando…
Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases
To enable the establishment of a drug discovery operation for neglected diseases, out of 2.3 million commercially available compounds 222 552 compounds were selected for an in silico library, 57 438 for a diverse general screening library, and 1 697 compounds for a focused kinase set. Compiling thes...
Autores principales: | Brenk, Ruth, Schipani, Alessandro, James, Daniel, Krasowski, Agata, Gilbert, Ian Hugh, Frearson, Julie, Wyatt, Paul Graham |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
WILEY-VCH Verlag
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2628535/ https://www.ncbi.nlm.nih.gov/pubmed/18064617 http://dx.doi.org/10.1002/cmdc.200700139 |
Ejemplares similares
-
From On-Target to Off-Target Activity: Identification and Optimisation of Trypanosoma brucei GSK3 Inhibitors and Their Characterisation as Anti-Trypanosoma brucei Drug Discovery Lead Molecules
por: Woodland, Andrew, et al.
Publicado: (2013) -
Discovery of Inhibitors of Trypanosoma brucei by Phenotypic Screening of a Focused Protein Kinase Library
por: Woodland, Andrew, et al.
Publicado: (2015) -
Development of Small-Molecule Trypanosoma brucei N-Myristoyltransferase Inhibitors: Discovery and Optimisation of a Novel Binding Mode
por: Spinks, Daniel, et al.
Publicado: (2015) -
Identification of Inhibitors of the Leishmania cdc2-Related Protein Kinase CRK3
por: Cleghorn, Laura A T, et al.
Publicado: (2011) -
Design, Synthesis and Biological Evaluation of Novel Inhibitors of Trypanosoma brucei Pteridine Reductase 1
por: Spinks, Daniel, et al.
Publicado: (2011)